喉頭がん治療の世界市場2019-2023

◆英語タイトル:Global Laryngeal Cancer Therapeutics Market 2019-2023
◆商品コード:IRTNTR31218
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年4月23日
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、喉頭がん治療の世界市場について調査・分析し、市場概要、市場環境、喉頭がん治療市場規模、種類別(生物学、低分子)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・喉頭がん治療の世界市場概要
・喉頭がん治療の世界市場環境
・喉頭がん治療の世界市場動向
・喉頭がん治療の世界市場規模
・喉頭がん治療の世界市場:業界構造分析
・喉頭がん治療の世界市場:種類別(生物学、低分子)
・喉頭がん治療の世界市場:地域別市場規模・分析
・喉頭がん治療の北米市場規模・予測
・喉頭がん治療のヨーロッパ・中東・アフリカ市場規模・予測
・喉頭がん治療のアジア太平洋市場規模・予測
・喉頭がん治療の主要国分析
・喉頭がん治療の世界市場:意思決定フレームワーク
・喉頭がん治療の世界市場:成長要因、課題
・喉頭がん治療の世界市場:競争環境
・喉頭がん治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The increasing number of reimbursement programs is one of the key factors expected to boost the laryngeal cancer therapeutics market growth in the forthcoming years. Various governments and vendors are launching patient assistance programs for reducing the high-cost burden associated with the treatment using therapeutics and providing the treatment at an affordable price. As a result, increasing number of patient assistance programs will lead the laryngeal cancer therapeutics market growth during the forecast period. Technavio’s analysts have predicted that the laryngeal cancer therapeutics market will register a CAGR of over 7% by 2023.

Market Overview

A growing number of strategic alliances

The increasing number of strategic alliances among vendors is expected to result in the launch of more advanced therapies and quicker approval. The laryngeal cancer therapeutics market has witnessed strategic alliance for the development of commercialization of drugs for the treatment of laryngeal cancer. This will drive the growth of the market during the forecast period.

Clinical trial failures

The heavy cost involved in recruiting patients for trials and the high cost of the drug cause a significant loss to vendors when a clinical trial fail. Hence, these clinical trial failures are expected to pose a threat to the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the laryngeal cancer therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be concentrated with the presence of a few market players. Several organizations are focusing on raising awareness about the head and neck cancer also provides funding for drugs and therapeutics for the treatment and cure of laryngeal cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Biologics – Market size and forecast 2018-2023

Small molecules – Market size and forecast 2018-2023

Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Co.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Merck & Co. Inc.

Sanofi

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of vendors classification

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Global laryngeal cancer therapeutics market pipeline: Overview

Exhibit 18: Global laryngeal cancer therapeutics market pipeline: Snapshot

Exhibit 19: Type – Market share 2018-2023 (%)

Exhibit 20: Comparison by type

Exhibit 21: Biologics – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 23: Small molecules – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Popular chemotherapies for treatment of laryngeal cancer

Exhibit 25: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by type

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 51: Bristol-Myers Squibb Co. – Product segments

Exhibit 52: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 53: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 54: Bristol-Myers Squibb Co. – Key offerings

Exhibit 55: Bristol-Myers Squibb Co. – Key customers

Exhibit 56: Eli Lilly and Co. – Vendor overview

Exhibit 57: Eli Lilly and Co. – Business segments

Exhibit 58: Eli Lilly and Co. – Organizational developments

Exhibit 59: Eli Lilly and Co. – Geographic focus

Exhibit 60: Eli Lilly and Co. – Segment focus

Exhibit 61: Eli Lilly and Co. – Key offerings

Exhibit 62: Eli Lilly and Co. – Key customers

Exhibit 63: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 64: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 65: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 66: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 67: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 68: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 69: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 70: Merck & Co. Inc. – Vendor overview

Exhibit 71: Merck & Co. Inc. – Business segments

Exhibit 72: Merck & Co. Inc. – Organizational developments

Exhibit 73: Merck & Co. Inc. – Geographic focus

Exhibit 74: Merck & Co. Inc. – Segment focus

Exhibit 75: Merck & Co. Inc. – Key offerings

Exhibit 76: Merck & Co. Inc. – Key customers

Exhibit 77: Sanofi – Vendor overview

Exhibit 78: Sanofi – Business segments

Exhibit 79: Sanofi – Organizational developments

Exhibit 80: Sanofi – Geographic focus

Exhibit 81: Sanofi – Segment focus

Exhibit 82: Sanofi – Key offerings

Exhibit 83: Sanofi – Key customers

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of vendors classification



【掲載企業】

Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[喉頭がん治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆